Jennifer Woyach, MD, Ohio State University College of Medicine, Columbus, OH, reports the efficacy of pirtobrutinib, a non-covalent BTK inhibitor (BTKi), in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have been previously treated with a covalent BTKi and potentially a BCL2 inhibitor (BCL2i), using data from the BRUIN study (NCT03740529). Pirtobrutinib demonstrated high overall response rates (ORR) in this patient population, irrespective of BCL2i exposure. This suggests the potential significance of continuing BTK inhibition post-covalent inhibition as a sequencing strategy in CLL/SLL. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
8 дек 2023
